Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVATION 2: IMNN-001 + NACT in Advanced Ovarian Cancer
NCT03393884Phase 2Active, not recruiting
- Sponsor
- Imunon, Inc.
- Start
- Sep 2018
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 2
01
Overview
A Phase 2 trial of IMNN-001 in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Imunon, Inc.. Started Sep 2018; status: active, not recruiting.
02
Drugs
IMNN-001
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03393884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393884.